Clarity AI Joins Institutional Investors Group on Climate Change (IIGCC), Strengthening Its Role in Shaping Sustainable Investment Through Data and Expertise
Clarity AI, the leading global sustainability tech company, announced today during COP29 that it has become an associate member of the Institutional Investors Group on Climate Change (IIGCC). This membership underscores Clarity AI's commitment to driving the sustainable investment market forward, empowering investors to address climate risk within their portfolios, and contributing to the global transition to a low-carbon economy.
As part of its membership, Clarity AI looks forward to contributing its expertise in climate data needs and potential solutions to IIGCC's working groups, helping to shape future investor guidance on key climate issues.
“Joining IIGCC is a significant step for Clarity AI as we continue our mission to help investors navigate the complexities of sustainable investment,” said Lorenzo Saa, Chief Sustainability Officer at Clarity AI, in Baku. “We’re excited to learn and contribute our insights with IIGCC members to promote frameworks that support a net-zero, climate-resilient future.”
IIGCC’s mission focuses on bringing the investment community together to make significant progress towards a net zero and climate resilient future by 2030. IIGCC helps more than 400 investor members to navigate implementation of climate considerations in portfolios, advocate for a more supportive policy environment, and undertake effective stewardship and engagement with companies, and the wider market, to create practical solutions that can make a real difference in tackling climate change.
Clarity AI supports investors with data and analytics capabilities to make more informed, climate-resilient investment decisions, in alignment with industry and regulatory standards such as the Net Zero Investment Framework (NZIF) or the Sustainable Finance Disclosure Regulation (SFDR) Principal Adverse Impacts (PAI).
“Our collaborative approach across the ecosystem helps us anticipate and address market changes,” said Saa. “As a tech company, we have the flexibility and agility to respond to these changes and meet our clients’ unique needs, whether they are seeking to align with regulations, signal their progress to the market, assess the credibility of companies’ transition plans or create climate-resilient products”.
Clarity AI is an active member within various groups, including the Future of Sustainable Data Alliance, the PRI, GFANZ, and the Sustainable Investment and Finance Associations. These memberships reinforce the company’s commitment to shaping the future of sustainable finance and further embedding Clarity AI in the broader climate finance ecosystem.
About Clarity AI
Clarity AI is the leading sustainability tech company, leveraging advanced technology and AI to provide data-driven environmental and social insights to investors, corporates, governments, and consumers. AI has been at the core of Clarity AI's offering from the start, supporting a fully flexible set of data solutions, insights, analytics capabilities, and tools used for portfolio management, corporate research and engagement, benchmarking, regulatory reporting, online banking, and e-commerce. Clarity AI was named a leader by independent research in The Forrester Wave: ESG Data & Analytics, Q3 2024.
Within the investment sector, Clarity AI serves a direct network of clients managing over $60 trillion in assets and includes firms like Invesco, Nordea, Lazard Asset Management, and Santander. Our strategic partnerships with financial institutions such as BlackRock, the London Stock Exchange Group (LSEG), BNP Paribas, Caceis, or SimCorp, allow thousands of users to access Clarity AI advanced data analytics capabilities through their usual investment platforms, ensuring a seamless workflow experience. Clarity AI has offices in North America, Europe, and the Middle East. For more information visit www.clarity.ai
About IIGCC
IIGCC brings the investment community together to work towards a net zero and climate resilient future. We create change the world needs by unlocking investor action on climate change.
We work with our members to address climate risk and ensure they are well positioned to make the most of investment opportunities offered by climate mitigation and adaptation efforts, ensuring that their investments contribute towards a better world for us all to live in.
Our team supports investors to create practical solutions that can make a real difference in tackling climate change – providing guidance and support on investment practices, policies and corporate behaviours that have real impact and deliver change that the world needs. For more information visit www.iigcc.org and @iigccnews
View source version on businesswire.com: https://www.businesswire.com/news/home/20241113625043/en/
Contacts
For any related inquiries, please contact:
Media contact Clarity AI
Aspectus Group
ClarityAI@aspectusgroup.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Global Cell and Gene Therapy Trials: Driving Innovation in Oncology and Beyond14.11.2024 14:05:00 CET | Press Release
Novotech, the global full-service clinical Contract Research Organization (CRO), has published its latest whitepaper, offering in-depth analysis and emerging trends and advancements within the rapidly evolving field of cell and gene therapies. The report provides critical insights into the growth of clinical trials, innovations and strategic opportunities, shaping the future of this field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241114441933/en/ Key Highlights from the Report: Global Clinical Trial Expansion: Over 1,500 drug candidates in development across phases 0 to III. CAR-T therapies account for 32% of the pipeline, primarily targeting hematological cancers. The global trial landscape experienced a 32.5% growth from 2019 to 2023, with Asia-Pacific leading in trial activity (44% of all trials). Oncology Focus: CAR-T and CAR-NK therapies represent ~30% of all cell and gene trials, with a strong focus on solid and
REPLY: the Board of Directors Approves the Quarterly Financial Report as of 30 September 202414.11.2024 13:52:00 CET | Press Release
Today, the Board of Directors of Reply [EXM, STAR: REY] approved the results as at 30 September 2024. The Group's consolidated turnover in the first nine months of the year reached €1,666.9 million, an increase of 7.7% compared to €1,548.0 million recorded on 30 September 2023. The indicators for the period are positive. Consolidated EBITDA was €275.5 million, equal to 16.5% of the consolidated revenues. As of September 2023 EBITDA was €235.8 million. EBIT, from January to September, reached €224.2 million, equal to 13.4% of the consolidated revenues. The corresponding 2003 figure was €187.7 million. Pre-tax profit, from January to September 2024, was €216.0 million, equal to 13.0% of the revenues. As of September 2023 pre-tax profit stood at €170.3 million. For the third quarter of the year, the Group’s performance is positive, with consolidated turnover for the period of €552.6 million compared to €509.1 million of the third quarter 2023. EBITDA, from July to September 2024, was equa
Experian Named to World’s Best Workplaces™ 2024 by Fortune and Great Place to Work ®14.11.2024 13:22:00 CET | Press Release
Experian today announced it was named one of the World’s Best Workplaces™ 2024 by Fortune and Great Place to Work®, which recognises a select 25 global companies that are building the best workplace cultures in the world. The honour highlights Experian’s people-first workplace culture that promotes inclusivity, fosters collaboration and innovation, and prioritises team member well-being, personal growth, and advancement. In its 14th year of producing this prestigious international list, Great Place To Work® surveyed 6.2 million employees worldwide on key factors that create great workplaces and analysed company workplace programmes that impact 18 million employees globally. Organisations were assessed on their efforts to create great workplaces and positively impact people and communities across multiple countries around the world. “This is a great recognition,” said Brian Cassin, Chief Executive Officer of Experian. “It’s a testament to the hard work, dedication, and creativity that o
Rogers Investment Advisors leads FSR Angel 1 LPS investment in XELA Robotics Expansion to Drive Global Ambitions14.11.2024 13:00:00 CET | Press Release
XELA Robotics Co., Ltd., (“XELA”), a pioneer in tactile sensing and advanced tactile AI-driven robotic solutions, today announced a significant 7-digit (USD) investment by FSR Angel 1 LPS (“FSR”), managed by Rogers Investment Advisors K.K.(“RIA”). The investment reinforces XELA’s vision to expand its global footprint while maintaining its position as a leader in tactile AI technology. The founding team will remain the majority shareholders of XELA, a company spun off from Waseda University, one of Japan’s most prestigious academic institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241114649471/en/ XELA Robotics CEO Alexander Schmitz with key investors from FSR Angel 1 LPS and Rogers Investment Advisors K.K., marking a pivotal step in our mission to expand globally and lead in AI-driven tactile sensing. (Graphic: Business Wire) XELA’s disruptive AI technology integrates tactile sensors to open new horizons for indus
BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer14.11.2024 12:00:00 CET | Press Release
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced its intent to change the Company’s name to BeOne Medicines Ltd., confirming its commitment to develop innovative medicines to eliminate cancer by partnering with the global community to serve as many patients as possible. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241114671168/en/ (Graphic: Business Wire) “Cancer, a leading cause of death worldwide, exacts an immense toll on individuals, families, and communities. No person, family, scientist, clinician, hospital, policy maker, company or country can or should face this devastating disease alone. We all must work together to win, which is why we are committed to playing a critical role and unifying the global community in the fight against cancer. Our focus is to not only bring innovative medicines to as many people as possible, but also to identify and address the challeng
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom